<DOC>
	<DOCNO>NCT00923416</DOCNO>
	<brief_summary>The goal study identify side effect cause implant marker via rectum . The investigator also try determine factor ( position marker ) influence risk side effect . The study procedure consist two questionnaire : The first complete immediately marker implantation second questionnaire complete radiotherapy planning .</brief_summary>
	<brief_title>Trans-Rectal Ultrasound-Guided ( TRUS ) Adverse Events</brief_title>
	<detailed_description>Precise localisation target organs become increasingly important routine use steep dose gradient conformal intensity modulate radiotherapy . This particularly challenging soft tissue target organ , prostate , displace relative bony anatomy . Although novel image technique develop direct visualisation soft tissue structure , contrast image quality currently limit . However , use radio-opaque intra-prostatic fiducial marker ( IPM ) high dose radiotherapy proven effective term improve accuracy , decrease toxicity .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Have biopsy confirm prostate cancer ( risk category ) Have 3 intraprostatic marker insert PMH prior radiotherapy Be willing provide write informed consent Be willing complete adverse event questionnaire</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Intra-Prostate Markers</keyword>
	<keyword>Transrectal Ultrasound</keyword>
	<keyword>Prostate Cancer Patients</keyword>
</DOC>